Bloomage Biotech(SH:688363) Xin Lang Cai Jing·2025-09-22 02:12Core Viewpoint - Huaxi Bio's stock price has shown fluctuations, with a year-to-date increase of 8.82% but a recent decline of 7.48% over the past five trading days, indicating potential volatility in investor sentiment [2]. Company Overview - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, is located in Jinan, Shandong Province. The company specializes in microbial fermentation and cross-linking technologies, developing bioactive materials that contribute to human health [2]. - The company has a comprehensive business model that spans from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Revenue Composition - The revenue composition of Huaxi Bio is as follows: 40.34% from skin science innovation transformation, 29.76% from medical terminal products, 27.70% from raw materials, and 2.17% from other sources [2]. Financial Performance - For the first half of 2025, Huaxi Bio reported a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% year-on-year [2]. Shareholder Information - As of June 30, 2025, Huaxi Bio had 32,500 shareholders, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Institutional Holdings - The top ten circulating shareholders include notable ETFs, with Huaxia SSE Sci-Tech Innovation Board 50 ETF holding 10.6429 million shares, a decrease of 244,800 shares from the previous period. Other ETFs have shown varying changes in their holdings [3].